PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Study Completion Date

2003-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if PEG-Intron is better tolerated and more efficacious than standard interferons (Roferon, Intron) in patients with Philadelphia-positive Chronic Myelogenous Leukemia. These patients should have previously received standard interferon therapy and have been intolerant, resistant, or have relapsed disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

NCT03547154

Chronic Myelogenous Leukemia

TERMINATED PHASE2/PHASE3

Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)

NCT00511121

Chronic Myeloid Leukemia

TERMINATED PHASE2

Ropeginterferon for Treatment Free Remission

NCT07105319

CML (Chronic Myelogenous Leukemia)

COMPLETED PHASE4

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

NCT00297570

Leukemia, Myeloid, Philadelphia-Positive

UNKNOWN PHASE3

A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia

NCT01227356

Health Care Quality Health Care Evaluation

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It has been shown that patients who experience complete hematologic or at least a partial cytogenetic response to interferon will have improved survival times. In addition, evidence exists that even patients who do not demonstrate a cytogenetic response to interferon treatment can still benefit from treatment, in terms of survival, compared to patients not treated with interferon. This indicates that if a patient is better able to tolerate interferon, he or she may have improved survival even without cytogenetic response. Preliminary studies suggest that PEG-Intron is more convenient for patients (administered once weekly rather than daily), is better tolerated than interferon, and can produce hematologic remission in interferon-a resistant patients. Phase II studies are needed to ascertain the overall hematologic and cytogenetic response rates to PEG-Intron in such patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myeloid, Philadelphia-Positive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SCH 54031

Peg Interferon Alpha-2B/PEG-Intron

Group Type EXPERIMENTAL

PEG-Intron

Intervention Type DRUG

Once weekly injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PEG-Intron

Once weekly injection.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SCH 54031 Peg Interferon Alpha-2B

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic phase CML, documented by the presence of Philadelphia chromosome or bcr/abl rearrangement at time of diagnosis, confirmed by either cytogenetics or PCR.
* WBC \>/= 3000/ul \</=100,000/ul.
* Patients must have received prior interferon therapy \& proven to have primary refractory disease, secondary resistance or intolerance to interferon-a
* Patient must have ECOG status of 0, 1, or 2
* Labs: SGOT/SGPT\<2xULN; serum bilirubin\<2xULN; serum creatinine \<2.0mg/dl
* Recovered from effects of major surgery
* Life expectancy \> 12 wks.
* Signed informed consent.
* Women of childbearing potential must have negative serum pregnancy test within 72 hrs prior to administration of PEG-Intron \& use effective contraception during the study.

Exclusion Criteria

* NO accelerated Phase CML patients with peripheral blood: blasts\>/=15%, basophils\>/=20%, blasts+promyelocytes\>/=30%, platelets\<100,000/ul (unrelated to therapy). Blastic phase CML:\>/=30% in peripheral blood/bone marrow.
* NO patients with known hypersensitivity to interferon-a.
* NO severe cardiovascular disease, i.e. arrhythmias requiring chronic treatment or congestive heart failure (NYHA classification III/IV).
* NO history of neuropsychiatric disorder requiring hospitalization.
* NO patients requiring therapy for refractory thyroid dysfunction
* NO patients with uncontrolled diabetes mellitus.
* NO patients who have had treatment for a 2nd malignancy in the past 5 yrs, except for localized basal cell/squamous cell carcinoma of the skin or cervical carcinoma in situ.
* NO pregnant or lactating patients.
* NO patients known to be actively using alcohol or drugs
* NO patients receiving any experimental therapy within 30 days of enrollment in study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No